High-efficiency 14-valent pneumococcal conjugate vaccine

Abstract

The invention relates to a high-efficiency 14-valent pneumococcal conjugate vaccine, which is formed by coupling and combining capsular polysaccharide extracted from fourteen types of serotype pneumococcuses and carrier protein; the fourteen types of the serotype pneumococcuses are 1, 2, 4, 5, 6A, 6B, 7F, 9N, 9V, 14, 18C, 19A, 19F and 23F; and the carrier protein is diphtherin non-toxic mutated protein CRM197, tetanus toxin protein and influenza haemophilus protein D. Compared with the prior pneumococcal conjugate vaccine, the high-efficiency 14-valent pneumococcal conjugate vaccine has the advantages that: (1) the cross-protection rate of the pneumococcuses of fourteen serotypes (1, 2, 4, 5, 6A, 6B, 7F, 9N, 9V, 14, 18C, 19A, 19F and 23F) reaches more than 90 percent; and (2) the high-efficiency 14-valent pneumococcal conjugate vaccine can generate effective protection on senior citizens which are susceptible to pneumonia and is suitable for children under two years old.

Description

Technical field: [0001] The invention relates to the field of immunology, in particular to a high-efficiency 14-valent pneumococcal conjugate vaccine for preventing pneumococcal infection. Background technique: [0002] Pneumococcus (S.pneumoniae), such as figure 1 As shown, the threat to the world is increasing day by day. The likelihood of pneumococcal disease flares during influenza is further increased by the spread of antibiotic-resistant infectious diseases and the fact that pneumococcal pneumonia often follows influenza infection. Diseases caused by Streptococcus pneumoniae have become an important public health problem worldwide. Pneumococcus has become the number one killer of children in the world, the specific statistics are as follows figure 2 shown. [0003] According to the statistics of the World Health Organization in 2005, an average of 1.6 million people die from this disease every year, including 700,000 to 1,000,000 children under the age of 5. In 2...

AI Technical Summary

Problems solved by technology

Therefore, polysaccharide vaccines have the following problems: (1) in young animals or infants, only a weak immune response can be produced, or even no immune response, and the immune response increases with age; (2) produce low-affinity antibodies, mainly It is IgM; (3) It only produces a short-term immune response, and does not have the immune memory and immune enhancement effect during repeated vaccination; (4) It is easy to produce immune tolerance; (5) Common adjuvants are not easy to be immune to this antigen enhanced effect

[0013] However, the data in my country show that the serotypes of pneumococcal infection strains are: 5, 6, 1, 19, 23, 14, 2, 4, and the coverage rate of Wyeth 7-valent pneumococcal conjugate vaccine to common pathogenic bacteria in my country is only 33.9%.

Wyeth 7-valent pneumococcal conjugate vaccine requires 4 injections, 860 yuan per injection, which is expensive and not conducive to promotion

Images